Advances in Urology / 2018 / Article / Tab 1

Review Article

Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors

Table 1

Prospective studies examining the use of initial salvage conventional-dose chemotherapy.

Author (year)NCDCT Regimen(s)Notable inclusion or exclusion criteriaEP/BEP as first-line therapyCR/PR to first-line therapyIR to first-line therapyCRMedian f/u (months)Durable remission

McCaffrey et al. [4]56VeIP or VIPNone53%36%64%36%5223%
Loehrerr et al. [5]135VeIPCisplatin-refractory patients excludeda100%100%0%50%72b24%
Kondagunta et al. [14]46TIPIncluded only patients with CR- or PR-negative marker to first line, gonadal primary, and <6 cycles of cisplatin in first line74%100%0%70%6963%
Fizazi et al. [17]37GIPIncluded only patients with CR or PR-negative marker to first line, gonadal primary, and <6 cycles of cisplatin in first line86%100%0%54%5351%

CDCT, conventional-dose chemotherapy; EP, etoposide plus cisplatin; BEP; bleomycin, etoposide, and cisplatin; IR; incomplete response; CR, complete response; f/u, follow-up; VIP, etoposide, ifosfamide, and cisplatin; VeIP, vinblastine, ifosfamide, and cisplatin; GIP, gemcitabine, ifosfamide, and cisplatin; aprogression at <3 weeks after completion of first-line chemotherapy; bminimal (not median) follow-up.